ULTIPLE YELOMA Mand Related Malignancies



Similar documents
5 th Heidelberg Myeloma Workshop

FOCUS ON BIOLOGICAL THERAPIES IN HEMATOLOGIC MALIGNANCIES

Regional Young Investigator SIC meeting. 5-6 March 2015

INTERNATIONAL RETREAT OF PhD STUDENTS IN IMMUNOLOGY June 2015

LIQUID BIOPSY: TRACKING CANCER

Scientific Programme

Genomics in Hematology

58th ANNUAL MEETING OF THE ITALIAN CANCER SOCIETY REVOLUTIONARY ROAD. VERONA SEPTEMBER Palazzo della GRAN GUARDIA. First Announcement

How To Organize A Conference On The Theory Of Science

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

Haploidentical Stem Cell Transplantation

Stem cells: the diverging goals of regenerative medicine and oncology ROME JULY 1-2, 2010 CALL FOR ABSTRACTS

A Focus on Multiple Myeloma

Promises and challenges of developing new drugs in oncology

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom

Promises and challenges of developing new drugs in oncology

5 February Bari, Italy

International Symposium on: Pain and Cough

Biogenic Amines 2011

FastTest. You ve read the book now test yourself

SKIN MELANOMA September 2006, Istanbul, TR

COPD: from the first cigarette to mechanical ventilation june Pav. 5. Nuove Patologie. Policlinico S.

Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

on End Stage Focus on Idiopathic

THE PRESENT AND THE FUTURE OF FERTILITY PRESERVATION

FIRST ITALIAN CHAPTER MEETING

Stem Cells, Cancer, Immunology and Aging

SPONSORSHIP/ADVERTIZING OPPORTUNITIES

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease

Mediterranean School of Oncology

International symposium on: The Impact of Genomic Deep Sequencing on

Centro CARDIOLOGICO Monzino - IRCCS

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

SPEAKERS AND CHAIRMEN

T u m o r D o r m a n c y

Multiple Myeloma. April 22-24, TORINO Centro Congressi Lingotto. Mario Boccadoro Alessandro Pileri PROGRAM. Presidents:

Independent Clinical Research in Oncology

Monday 27 th October ,00-14,00 Registration 12,30-14,00 Welcome Buffet

FIRST INTERNATIONAL PORTO PIRGOS CONFERENCE ON ADVANCES IN NEUROSCIENCE. Porto Pirgos Hotel ( Parghelia (VV), Calabria, Italy

Advances in Biology and Treatment of Malignant Brain Gliomas

National Workshop of Hematology The TP53 Workshop

Future strategies for myeloma: An overview of novel treatments In development

Centro Congressi Hotel Michelangelo ORGANIZING SECRETARIAT. Con il patrocinio di SIE Società Italiana di Ematologia

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

MS: from disease management to patient management

Breast Pathology Masterclass 2016

Rome, May 2016

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

A Career in Pediatric Hematology-Oncology? Think About It...

Saturday 24 September Lunch break and trade exhibition

pulmonary hypertension bologna 2012 Royal Hotel Carlton - Bologna - Italy Under the aegis of alma mater studiorum università di bologna

7 th Course on Paediatric Reconstructive Urology HOW WE DO IT. Rome, June 2012

3 INTERNATIONAL COURSE ON FUNCTIONAL RECONSTRUCTIVE SURGERY OF PELVIC FLOOR. June 3-4-5, Università degli Studi di Milano Bicocca Monza (Italy)

The Copernican Revolution in Ischemic Heart Diseases: the day after

INTRAOPERATIVE MONITORING OF LARYNGEAL NERVES IN THYROID SURGERY

Atahotel Executive Milan, Italy October 21, 2011

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

PULMONARY HYPERTENSION. This meeting is fully sponsored by GlaxoSmithKline and jointly organised with the Meeting Faculty and GlaxoSmithKline

AOSpine Masters Symposium Adult deformity of the cervical, thoracic and lumbar spine

International Summer School of Renal Pathology. 20th - 31st July 2015 Bari (Italy)

American College of Allergy, Asthma & Clinical Immunology (ACAAI), USA International Center for Interdisciplinary Studies of Immunology Washington

Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children

Financialisation and sustainability

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

A LIFE THAT IS BORN MAKES LIFE GROW. CORD BLOOD: CURRENT EXPERIENCES AND FUTURE PROGRAMMES

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD

CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010

FAMILIAL CANCER ESO, CNIO AND NRCO CONFERENCE ON May 2016 Madrid, Spain. Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H.

Ocular Surface Diseases Course 2016 MIAMI,FLORIDA. Bascom Palmer Eye Institute. Sponsored by the University of Miami Miller School of Medicine

CANCER SUMMER SCHOOL 2014 PROGRAM

in ANAESTHESIA, INTENSIVE CARE and PAIN in NEONATES and CHILDREN

SAPIENZA UNIVERSITA DI ROMA UNIVERSITY OF CALIFORNIA SAN DIEGO FIRST ANNUAL CONFERENCE ON TRANSLATIONAL RESEARCH IN MEDICINE

eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl

UPDATE ON BONE METASTASES

Evaluation of Public Policies: Learning from Comparative Multilevel Experiences

Disclosures for Elena Zamagni

International Symposium on. Enterococci in Foods. Functional and Safety Aspects. 2nd Announcement and Call for Papers

29 January Rome, Italy

CONTRASTS IN PHARMACOLOGY 2.0

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological

Resolving Cancer Heterogeneity:

BONE MARROW FAILURE DISEASE SYMPOSIUM SATURDAY SEPTEMBER 27, 2014 AN UPDATE ON THE LATEST IN DIAGNOSIS AND TREATMENT

1 st International Course on Kidney Transplantation: Prevention of graft rejection

CCM National Project PRECIOUS Care of patients with acquired severe brain injury in Italy. In collaboration with

2 Year ( ) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

How To Understand And Treat Pain In Neurobiological Conditions

Transcription:

Under the auspices of: ULTIPLE and Related Malignancies Società Italiana di Medicina Interna Italian Society of Immunology Clinical Immunology and Allergology SIE Società Italiana di Ematologia Società Italiana di Ematologia Sperimentale Ordine dei Medici Chirurghi ed Odontoiatri della Provincia di Bari Provincia di Bari Comune di Bari Scuola di Specializzazione in Medicina d Emergenza-Urgenza Scuola di Specializzazione in Oncologia Medica Scientific Secretariat Simona Berardi Annunziata De Luisi Michele Moschetta Vito Racanelli Antonia Reale Roberto Ria Domenico Ribatti

Presentation In the last 15 to 20 years significant advancements in the understanding of the pathophysiology of multiple myeloma and related malignancies have led to the adoption of new and effective therapies. Thus, the time has come for a thorough biological and clinical update. In planning this international meeting, we have indeed kept in mind this aim which will hopefully provide specialists in Hematology, Oncology and Internal Medicine as well as young researchers, residents, doctoral and undergraduate students with a unique opportunity to deepen and update their knowledge with regard to the available and emerging developments in the biology and management of multiple myeloma and related malignancies. A number of internationally recognized speakers, coming from our own and other countries, are expected to deliver state-of-the-art lectures on cutting edge topics. These will include genetic and molecular features of myeloma biology, mechanisms of disease progression, novel diagnostic approaches, new therapeutic molecules and combinations thereof specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation will also be the object of intensive scrutiny. Finally, two hot points sessions have been planned in order to provide basic and clinical researchers with the opportunity to present and discuss the results of their endeavours. Based on these premises, we are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by multiple myeloma and cognate tumors may now be faced with more rational and more effective achievements. Franco Dammacco, Angelo Vacca

Faculty Niels Abildgaard Odense, DK Henk M. Lokhorst Utrecht, NL Andrea Bacigalupo Genoa, I Sagar Lonial Atlanta, USA Vincenzo Barnaba Rome, I Joan Bladé Barcelona, E Mario Boccadoro Turin, I Ivan Borrello Baltimore, USA Federico Caligaris Cappio Milan, I Michele Cavo Bologna, I Michele Cea Boston, USA Marta Chesi Scottsdale, USA Paolo Corradini Milan, I Franco Dammacco Bari, I Madhav V. Dhodapkar Yale, USA Hermann Einsele Würzburg, D Anna Falanga Bergamo, I Rafael Fonseca Scottsdale, USA Irene Ghobrial Boston, USA Hartmut Goldschmidt Heidelberg, D Roman Hájek Brno, CZ Jean-Luc Harousseau Paris, F Dirk Hose Heidelberg, D Sundar Jagannath New York, USA Robert Kyle Rochester, USA Ola Landgren Bethesda, USA Massimo Massaia Guillermo Martín-Reyes Giampaolo Merlini Fortunato Morabito Philippe Moreau Michele Moschetta Arnon Nagler Antonio Palumbo Francesco A. Piazza Guy Pratt Vito Racanelli Noopur Raje Roberto Ria Aldo Roccaro Gianpietro Semenzato Franco Silvestris Pieter Sonneveld Giorgina Specchia Andrew Spencer Francesco Spina Kathrin Strasser-Weippl Evangelos Terpos Steven P. Treon Angelo Vacca Karin Vanderkerken Turin, I Malaga, E Pavia, I Cosenza, I Nantes, F Boston, USA Tel-Hashomer, IL Turin, I Padua, I Birmingham, UK Bari, I Boston, USA Bari, I Boston, USA Padua, I Bari, I Rotterdam, NL Bari, I Melbourne, AUS Milan, I Wien, A Athens, GR Boston, USA Bari, I Brussels, B Xavier Leleu Lille, F Qing Yi Cleveland, USA

Program 12.00 Registration of participants 14.00 Welcome address 14.45-15.00 Welcome speech and orientation Franco Dammacco Angelo Vacca 15.00-16.40 Workshop 1 - Biology and Immunology Chairpersons: Vincenzo Barnaba, Federico Caligaris Cappio 15.00-15.20 Harnessing microenvironment to halt plasma cell tumors Irene Ghobrial 15.20-15.40 Rational therapeutic immune modulation in multiple myeloma Marta Chesi 15.40-16.00 Immunological synapse in myeloma Madhav V. Dhodapkar 16.00-16.20 The bone marrow as a privileged site of immune suppression: lessons from gamma delta T cells 16.20-16.40 Leading edge researches to target plasma cells and microenvironment 16.40-17.10 Coffee break 17.10-18.50 Workshop 2 - Bone Disease and Kidney Impairment Chairpersons: Guillermo Martín-Reyes, Gianpietro Semenzato 17.10-17.30 Bone markers in multiple myeloma what have they taught us? What s their clinical use? Massimo Massaia Michele Cea Niels Abildgaard 17.30-17.50 Treating bone disease in 2013: current and novel therapies Noopur Raje 17.50-18.10 Multiple myeloma and kidney impairment Guillermo Martín-Reyes Thursday, November 7, 2013 18.10-18.30 Survival of myeloma patients with acute kidney injury Fortunato Morabito 18.30-19.30 HOT POINTS Chairpersons: Roman Hájek, Evangelos Terpos 18.30-18.50 IMWG 2013 recommendations for the management of Evangelos Terpos myeloma-related bone disease 18.50-19.10 Markers predicting transition of MGUS into myeloma Roman Hájek 19.10-19.30 Oncogenic signaling pathways in multiple myeloma Francesco A. Piazza Discussion

9.00-10.40 Workshop 3 - Diagnosis and Prognostic Factors Chairpersons: Joan Bladé, Ola Landgren 9.00-9.20 Imaging in multiple myeloma Francesco Spina 9.20-9.40 FISH and prognosis in multiple myeloma: how to detect prognostic subclones? 9.40-10.00 Myeloma and its precursor disease: from symptoms to markers Rafael Fonseca Ola Landgren 10.00-10.20 Prognostic factors as a guide to treatment Dirk Hose 10.20-10.40 Redefining risk in the modern era Joan Bladé Friday, November 8, 2013 10.40-11.00 Coffee break 11.00-12.20 Workshop 4 - Clinical Features Chairpersons: Hartmut Goldschmidt, Guy Pratt 11.00-11.20 Minimal residual disease Hartmut Goldschmidt 11.20-11.40 Quality of life among multiple myeloma patients Kathrin Strasser-Weippl 11.40-12.00 New guidelines for pain management in multiple myeloma Roberto Ria 12.00-12.20 Immunodeficiency in myeloma and treatment Guy Pratt 12.20-13.30 Lunch 14.00-15.40 Workshop 5 - First Line Therapy Chairpersons: Antonio Palumbo, Andrew Spencer 14.00-14.20 Upfront treatment in young patients: what induction and consolidation therapy? 14.20-14.40 Upfront treatment in young patients: what maintenance therapy? Michele Cavo Andrew Spencer 14.40-15.00 Upfront therapy in elderly patients Antonio Palumbo 15.00-15.20 Auto-SCT vs novel agents in multiple myeloma Arnon Nagler 15.20-15.40 Integrating novel agents into first-line therapy Hermann Einsele

15.40-16.10 LECTURE Chairperson: Franco Dammacco Can multiple myeloma become a chronic disease? Robert Kyle 16.10-16.30 Coffee break 16.30-18.30 Workshop 6 - Relapse/Refractory Myeloma and Supportive Care Chairpersons: Andrea Bacigalupo, Michele Cavo 16.30-16.50 Transplant at relapse Andrea Bacigalupo 16.50-17.10 Personalized therapy in the relapsed/refractory patient Pieter Sonneveld 17.10-17.30 Cure vs control Henk M. Lokhorst 17.30-17.50 Pomalidomide-based therapy for relapsed/resistant disease Sundar Jagannath 17.50-18.10 Thrombotic issue in multiple myeloma Anna Falanga 18.10-18.30 Management of anemia in multiple myeloma Franco Dammacco 18.30-19.30 HOT POINTS Chairpersons: Aldo Roccaro, Giorgina Specchia 18.30-18.50 Systems of myeloma cell dissemination Aldo Roccaro 18.50-19.10 Active vaccination to halt aggressive myeloma Qing Yi 19.10-19.30 Role of endothelial progenitor cell in Multiple Myeloma Michele Moschetta Friday, November 8, 2013 Dinner

8.30-9.00 LECTURE Chairperson: Paolo Corradini Future directions in transplant in conjunction with novel drugs Jean-Luc Harousseau 9.00-10.20 Workshop 7 - The Newest Drugs Chairpersons: Sagar Lonial, Franco Silvestris 9.00-9.20 Histone deacetylase inhibitors Karin Vanderkerken 9.20-9.40 The new proteasome inhibitors Philippe Moreau 9.40-10.00 Monoclonal antibodies Sagar Lonial Saturday, November 9, 2013 10.00-10.20 Systems of resistance to antiangiogenesis in multiple myeloma and therapeutic approaches 10.20-10.40 Coffee break 10.40-11.00 LECTURE Chairperson: Hartmut Goldschmidt Early vs late transplant 11.00-12.40 Workshop 8 - Plasma Cell Dyscrasias and Management Chairpersons: Ivan Borrello, Massimo Massaia Angelo Vacca Mario Boccadoro 11.00-11.20 Pulsed dendritic cells to plasmocytoid cells Vito Racanelli 11.20-11.40 Role of T cells in myeloma immunity: perspectives for therapy Ivan Borrello 11.40-12.00 New strategies for targeting AL amyloidosis Giampaolo Merlini 12.00-12.20 Which biomarkers for Waldenström's macroglobulinemia? 12.20-12.40 Genomic revelations and targeted therapy of Waldenström s macroglobulinemia Xavier Leleu Steven P. Treon Discussion Closing Franco Dammacco Angelo Vacca

General Information CONGRESS VENUE Villa Romanazzi Carducci Via G. Capruzzi 326 Bari - ITALY Tel. +39-080-5427400 REGISTRATION FEE The registration fee is 100,00 + VAT and includes: Participation to all scientific sessions Congress kit Welcome reception Coffee breaks Lunch Applications for registration will be processed in the order they are received. Please send application to the Organizing Secretariat by fax (+39-080-9905359) or by e-mail (info@meeting-planner.it) using the attached form. Attendants shall check that places are available and that their registration has been finalized. DINNER A dinner will be organized on Friday, November 8, 2013. Tickets can be purchased in advance (please refer to the registration form) or on site at the registration desk. HOTEL RESERVATION Meeting Planner has selected hotels with various price categories. For further information please contact the Organizing Secretariat. METHODS OF PAYMENT Bank transfer to Meeting Planner srl UniCredit Banca - IBAN: IT 21 X 0200804024 000010278286 BIC-SWIFT UNCRITM1H04 Please write the title of the Congress Multiple Myeloma 2013 and the participant s name on the bank transfer Credit cards: VISA or MasterCard only

CANCELLATION Cancellation of registration and hotel reservation must be notified in writing to the Congress Secretariat. Registration fee and hotel reservations can be refunded if cancellation are made within October 4, 2013. After this date no refund will be possible. Refunds will be processed after the Congress. CONTINUING MEDICAL EDUCATION (CME) This Congress has been assigned no 10 credits. This training event is for 200 surgeons specialized in Internal Medicine, Oncology, Hematology, Emergency Medicine, Primary Care Medicine, Biologists. Please note that CME credits may be acquired and certified once the following requirements have been fulfilled: Participation in the entire training event (100% of total hours) Complete documentation entirely filled in Passing the CME evaluation questionnaire (minimum passing score: 75%) There are no exceptions to these requirements. Attendants are obliged to directly receive a maximum of 1/3 of the credits for the three-year period from 2011 to 2013. LANGUAGE The official language is English. No simultaneous translation will be available. BADGE Upon registration at the Congress Secretariat desk, all participants will receive an identification badge. Access to the congress area will be granted only to participants wearing their identification badge. SLIDE CENTRE A slide centre will be operating during the Congress. GENERAL GUIDELINES The Congress Organizers invite all Speakers to rigorously respect the time assigned established for the presentation of their work. Chairs shall be responsible for the fulfillment of the presentation time schedule.

POSTERS The deadline for the submission of poster abstracts is September 9, 2013. Abstracts should be submitted via e-mail to the following address: stella@meeting-planner.it. Please send a word file attachment fulfilling the following indications: Language: English File format: Word Words: max 600 (including titles, authors and affiliations) Font: Garamond Size: 12 Double spacing Title: concise, in bold, small letters Authors (in upper/lower cases in the following way): 1. Initial of the first name in upper case, surname with first letter in upper case (i.e. J. Smith) 2. Affiliation needs to contain what follows (the street address is not needed): Unit or Section, Department, University and/or Hospital, Town, Country 3. In case of multiple affiliations, please superscribe the relevant numbers 4. Please put a comma and a space between the names of the authors 5. Please put a semicolon between the authors affiliations 6. Please put a space line to separate the title from the authors, the authors from the affiliations, and the affiliation from the text A maximum of two references can be included Acknowledgements can be included at the end of the abstract Figures and tables are not accepted Standard abbreviations are accepted, other acronyms should be written in extenso the first time they appear in the abstract Authors will be notified of acceptance by October 18, 2013. Posters (70 cm width and 100 cm height) should be on display for the entire duration of the Congress. Poster viewing will be possible during coffee breaks time. Authors are kindly requested to be present for discussion during these times.